Peptide Profile

Cerebrolysin

Porcine Brain-Derived Neurotrophic Peptide Mixture

Overview

Composition

Mixture of low-molecular-weight peptides and amino acids produced from purified porcine brain proteins.

Mechanism of Action

Proposed to mimic or support neurotrophic-factor-like signaling, neuronal survival, synaptic plasticity, neuroprotection, and recovery pathways after neurologic injury

Primary Effects

Studied in stroke recovery, traumatic brain injury, Alzheimer disease, vascular dementia, and cognitive impairment, with mixed evidence and jurisdiction-specific medical use

Discovery & Background

Developed as a neuropeptide preparation for neurologic disorders and used in parts of Europe, Asia, and other regions

Clinical research has included randomized trials and meta-analyses in acute ischemic stroke, dementia, and neurorecovery, with conflicting conclusions depending on endpoint and study quality

Not FDA-approved in the United States; used as a prescription medicine in some countries

Research Overview

The evidence base is broader than many research peptides but remains mixed; systematic reviews in acute ischemic stroke have found uncertain or limited clinically meaningful benefit for major outcomes

01
Cochrane reviews in acute ischemic stroke report no clear reduction in all-cause death and uncertainty around functional benefit
02
Some meta-analyses and regional trials report improvements in neurologic scales or recovery endpoints, but heterogeneity and bias concerns remain
03
Dementia studies suggest possible cognitive or global-function signals, but evidence quality varies
04
It should not be treated as a substitute for guideline-directed acute neurologic care
05
Use should be clinician-directed, especially in stroke/TBI contexts where standard care timing matters

Region-specific medical use; not FDA-approved

Safety Considerations

Monitoring

Neurologic status and functional outcomes
Allergic reactions or infusion reactions
Seizure history and neurologic comorbidities
Renal function and medication interactions when clinically relevant

Side Effects

Reported

Headache, dizziness, agitation, sweating, or nausea
Fever, chills, or appetite changes have been reported
Rare hypersensitivity reactions

Clinical caution

Potential seizure risk in susceptible patients
Porcine-derived composition may be relevant for allergy or acceptability concerns

Contraindications

Known hypersensitivity to Cerebrolysin or porcine-derived components
Epilepsy or seizure disorders without clinician guidance
Severe renal impairment is commonly listed as a caution/contraindication in product labeling
Pregnancy or breastfeeding unless specifically directed by a physician

Educational Notice

Cerebrolysin is a prescription neuropeptide mixture in some countries but is not FDA-approved in the United States. Evidence is mixed and indication-specific.

References